OXALIPLATIN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) MODEL

Animals

Studies are conducted in adult male and female Sprague Dawley rats (Envigo) in an AAALAC-accredited facility with approval from an Institutional Animal Care and Use Committee, and implemented in accordance with the Guide for the Care and Use of Laboratory Animals 8th Edition (National Research Council, 2011) with standards set by the National Institutes of Health.

CIPN induction

Oxaliplatin is a commonly used chemotherapeutic agent in the platinum-complex class which has been shown to produce sensory neuropathy, including neuropathic pain. Administration of oxaliplatin (3 mg/kg, i.v.) twice a week over 4 consecutive weeks in rats is an established model of chemotherapy-induced peripheral neuropathy (CIPN) resulting in mechanical and cold allodynia (Boyette-Davis et al., 2011; Xiao et al., 2012).

Study design

In the oxaliplatin CIPN model, mechanical allodynia using von Frey filaments and cold allodynia using acetone evaporation are assessed using appropriate group sizes determined by power analysis. Male and female rats (n=8-10) are evaluated in separate cohorts. Dose-responses are investigated, and vehicle and positive control groups are included to establish the validity of the experiment. The experimenter is blinded to the treatments, and dosing is performed by an independent experimenter.

The area of the hind paw tested with von Frey filaments or acetone is located in the center of the plantar surface, avoiding the foot pads (X on Figure 1A).

Experimental outcomes

Hind paw mechanical allodynia testing using von Frey filaments

Paw withdrawal threshold (PWT) is assessed using the up-down method (Chaplan et al., 1994) for both the left and right hind paws prior to CIPN induction (Figure 1B). The development of hind paw tactile hypersensitivity is determined by testing the animals using von Frey filaments once per week during Weeks 5-6. During week 7, rats with average PWT ≤5.0g are included in the subsequent testing of the asset’s efficacy to treat mechanical allodynia in oxaliplatin CIPN rats. Animals are balanced across treatment groups based on body weight and post-oxaliplatin PWT.

Hind paw cold allodynia using acetone evaporation

The number of positive responses to acetone trials (Choi et al., 1994) is assessed for both the left and right hind paws prior to CIPN induction (Figure 1C). During Week 4, all rats receive cold priming with acetone. The development of hind paw cold hypersensitivity is determined by testing the animals during Week 5. During Week 6, rats with average scores ≥2 are included in the subsequent testing of the asset’s efficacy to treat cold allodynia in oxaliplatin CIPN rats. Animals are balanced across treatment groups based on body weight and post-oxaliplatin number of positive responses to acetone trials.

This work was conducted by PsychoGenics Inc. (Paramus, NJ) in collaboration with PSPP, NINDS, NIH under contract # 75N95019D00026